ClinicalTrials.gg
RecruitingNCT07253350ROTONECUpdated Jan 30, 2026

Effectiveness of Endorotor PED® System Versus Conventional Endoscopic Techniques for the Management of Walled-off Pancreatic Necrosis in Acute Necrotizing Pancreatitis: Randomized Single-blinded Controlled Superiority Trial and Cost-utility Analysis

An interventional study of Endorotor Group and Conventional group in Acute Necrotizing Pancreatitis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a national single-blinded prospective multicenter randomized (1:1) controlled trial, with two parallel arms, using a PROBE methodology, including patients with complicated acute necrotizing pancreatitis who require DEN of WON collection after endoscopic drainage. We will compare 2 groups: conventional DEN and DEN with Endorotor®. The study will be offered to all consecutive patients fulfilling the eligibility criteria after endoscopic drainage for WON. Since the time between drainage and the first necrosectomy session is usually at least 48 hours a period of at least 24h will be allowed for the patient to consider options to participate or not. Information and collection of informed consent will be done by an investigating physician.

02

Conditions studied

  • Acute Necrotizing Pancreatitis

Keywords

  • endoscopic necrosectomy
  • necrotic pancreatic collection
03

In context

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

This study's planned enrollment of 64 is close to the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.

Browse Pancreatitis, Acute Necrotizing studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18years
  • ASA\<5
  • CT scan less than 7 days old
  • Hospitalized for acute necrotizing pancreatitis, whatever the cause, and who have undergone drainage of pancreatic collections for the following indications according to the revised Atlanta criteria (infection, organ compression, persistent organ failure)
  • Have need for at least one DEN session despite endoscopic drainage (persistence of clinical symptoms or sepsis >48h after drainage with collection still visible)

Exclusion criteria

Exclusion Criteria:

  • No endoscopic drainage in place for the management of WON
  • Have already had a DEN session (endoscopic or else) before screening for inclusion
  • Life-expectancy \< 1year (advanced cancer, etc)
  • Known haemostasis disorder (chronic thrombocytopenia, haemophilia, etc.)
  • Pregnant or breastfeeding woman
  • Subject deprived of freedom, subject under a legal protective measure
  • Non-affiliation to a social security regimen or CMU
  • Patient or person of confidence (if present at the time of inclusion) opposing the patient's participation in research
  • Subject already involved in another interventional clinical research
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Endorotor Group

    DEN will be performed with Endorotor 3.2 or ENDOROTOR PED® system depending on the position of cystoenterostomy.

    Device: Endorotor Group

  • Active comparator
    Conventional group

    DEN is performed conventionally with abundant lavage and mechanical debridement using a non-dedicated material (diathermic loop, polypectomy or Dormia basket) to catch pieces of necrosis

    Other: Conventional group

Interventions

  • DeviceEndorotor Group

    DEN will be performed with Endorotor 3.2 or ENDOROTOR PED® system depending on the position of cystoenterostomy. Endorotor 3.2 is slimmer and enters WON more easily when the transgastric access is located in the upper portion of the stomach). If needed: lavage, aspiration and conventional mechanical debridement could be used in addition during an ENDOROTOR-based DEN session.

  • OtherConventional group

    DEN is performed conventionally with abundant lavage and mechanical debridement using a non-dedicated material (diathermic loop, polypectomy or Dormia basket) to catch pieces of necrosis

06

What researchers measure

Primary outcomes

  1. evaluate the effectiveness of the Endorotor PED® device versus conventional technique for the endoscopic management of symptomatic walled-off necrosis during necrotizing acute pancreatitis.

    The effectiveness of the operative approach (Endorotor 3.2/PED® or conventional technique) will be assessed by the period in days between the first DEN session and the confirmed complete necrosis resolution.

    Time frame: 5 month

Secondary outcomes

  1. number of death

    Time frame: 10 month

  2. number of new-onset multiple organ failure

    Time frame: 10 month

  3. number of visceral perforation

    Time frame: 10 month

  4. number of arterial perforation

    Time frame: 10 month

  5. number of pancreatic-cutaneous fistulas

    Time frame: 10 month

  6. number of sepsis

    Time frame: 10 month

  7. number of abscess

    Time frame: 4 month

  8. number of Bleeding of any severity

    Time frame: 4 month

  9. number of Need for surgery (video-assisted retroperitoneal debridement or open surgery)

    Time frame: 4 month

  10. number of Need for "multigate" strategy with the installation of a percutaneous drain

    Time frame: 4 month

  11. time to total recovery of acute pancreatitis

    Time frame: 16 month

  12. Total time of all DEN sessions in minutes

    Time frame: 4 month

  13. Total number of DEN sessions

    Time frame: 4 month

  14. Number of days of antibiotic treatment

    Time frame: 4 month

  15. operative difficulty of DEN assessed by endoscopists

    A Likert score will be used to assess the ease of use to maneuver device by endoscopist, from 0 (most difficult surgery imaginable) to 10 (easiest).

    Time frame: 4 month

  16. number of issues with Endorotor PED® device

    Failure types and number of occurrences

    Time frame: 4 month

  17. Number of days of hospitalization: In intensive care unit

    Time frame: 16 month

  18. Number of days of hospitalization: In conventional unit

    Time frame: 16 month

  19. Number of days of hospitalization in rehabilitation unit

    Time frame: 16 month

  20. quality of life of patients during and after hospitalization

    EQ-5D-5L score at the end of hospitalization and during follow-up's visits

    Time frame: 16 month

  21. Total hospital costs in acute care per patient Endorotor

    Time frame: 16 month

07

Study locations

1 of 1 sites recruiting
  • Hospital Beaujon, APHP
    Clichy, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2029, 38 months after the start.

Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Nov 2029
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07253350
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Jan 20, 2026
Primary completion
Mar 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Jan 30, 2026

Study contacts

Frederic Prat, MD PHD
Contact
frederic.prat@aphp.fr
01 40 87 56 63 ext. +33
Diane Lorenzo, MD PHD
Contact
diane.lorenzo@gmail.com
01 40 87 56 63 ext. +33
frederic Prat, MD PHD
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion